Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 34 Rectal Neoplasms 22 Stomach Neoplasms 17 Triple Negative Breast Neoplasms 16 Colorectal Neoplasms 14 Neoplasm Metastasis 10 Adenocarcinoma 9 Pancreatic Neoplasms 8 Esophageal Neoplasms 8 Adenocarcinoma Of Esophagus 7 Neoplasms 5 Nasopharyngeal Carcinoma 5 Biliary Tract Neoplasms 5 Parkinson Disease 4, Autosomal Dominant Lewy Body 4 Colonic Neoplasms 4 Carcinoma, Non-Small-Cell Lung 4 Esophageal Squamous Cell Carcinoma 3 Squamous Cell Carcinoma of Head and Neck 2 Spinocerebellar Degenerations 2 Ovarian Neoplasms 2 Neoplasm, Residual 2 Locally Advanced Rectal Cancer 2 Carcinoma 2 Anus Neoplasms 2 Advanced Solid Tumour 2 Somatostatinoma 1 Solid Tumors 1 Resectable Colon Cancer 1 Rectal Cancer Patients 1 Peritoneal Neoplasms 1

Interventions

Carboplatin 3 durvalumab 2 Tretinoin 2 Paclitaxel 2 Irinotecan 2 zanidatamab 1 veliparib 1 tucatinib 1 trilaciclib 1 trebananib 1 trastuzumab duocarmazine 1 tegafur-gimeracil-oteracil 1 talazoparib 1 sarilumab 1 pexidartinib 1 pertuzumab 1 pembrolizumab 1 patritumab 1 olaparib 1 niraparib 1 neratinib 1 ganitumab 1 dostarlimab 1 cemiplimab 1 abemaciclib 1 Trastuzumab 1 Surgical Procedures, Operative 1 Standard of Care 1 STA 9090 1 SGN-LIV1A 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Pathologic Complete Response × Capecitabine × 90 days × Clear all

NCT07472868 2026-03-16

MEND-IT II

Catharina Ziekenhuis Eindhoven

Phase 3 Not yet recruiting

Pathologic Complete Response

Data powered by HemOnc (CC BY 4.0) Colophon ⚡